Intravenous flecainide versus Amiedarone fof recent-onset atrial fibrillation

摘要: In a randomized, double-blind, controlled study of 98 patients with atrial fibrillation (AF) (present for > or = 30 minutes, 100 beats/min), intravenous flecainide (2 mg/kg, maximum 150 mg) was compared amiodarone (7 mg/kg) and placebo. Exclusion criteria included significant left ventricular dysfunction, inotrope dependence, recent antiarrhythmic therapy, hypokalemia, pacemaker dependence. Reversion to stable sinus rhythm within 2 hours starting medication considered likely be due drug effect. Twenty 34 (59%) given flecainide, 11 32 (34%) amiodarone, 7 (22%) placebo reverted in < after (chi-square 9.87, p 0.007). More than (p 0.005; odds ratio 5.1, 95% confidence interval 1.54 17.5). There no difference between amiodarone. However, 8 there were differences reversion the treatment groups: (n 23, 68%), 19, 59%), 18, 56%). Amiodarone promptly reduced rate, this effect maintained those whose unsuccessful: more effective controlling rate. Adverse effects not significantly different 3 groups. Thus, results earlier AF does Amiodarone, although less reverting AF, slows rapid response.(ABSTRACT TRUNCATED AT 250 WORDS)